IP Library › Granted Patent US 12,385,920
Granted Patent B2
US 12,385,920 · App. 17/511,327 · Granted Aug 12, 2025

IL-6 signaling and breast cancer

Inventor: Peter P. Lee (San Marino, CA)
Assignee: CITY OF HOPE
G01N33/57415C12Q1/6886G01N33/6869C12Q2600/118C12Q2600/158G01N2333/4703G01N2333/5412G01N2333/7155G01N2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,385,920
App. No.
17/511,327
Granted
Aug 12, 2025
Kind
B2
Abstract

The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Claims (9)

1. A method for treating breast cancer in a patient in need thereof, the method comprising:

(i) isolating T cells from peripheral blood mononuclear cells obtained from the patient;

(ii) culturing the T cells in a Th17 differentiation medium;

(iii) identifying the patient as having an increased risk for breast cancer relapse when the patient has:

(a) a lower level of differentiated Th17 cells relative to a control; or

(b) a lower level of IL-17 production by the Th17 cells relative to a control; and

(iv) administering to the patient an effective amount of an anti-cancer agent, wherein the anti-cancer agent is anastrozole, capecitabine, cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil, gemcitabine, goserelin, lapatinib, letrozole, neratinib, paclitaxel, tamoxifen, toremifene, trastuzumab, vinblastine, or a combination of two or more thereof.

2. The method of claim 1 , wherein the T cells are CD4 + T cells.

3. The method of claim 1 , wherein the T cells are naïve CD4 + T cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 16, 2025
From: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
To: UNITED STATES GOVERNMENT
Reel/Frame 070863/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2021
From: LEE, PETER P.
To: CITY OF HOPE
Reel/Frame 058180/0025 →
Continuity (4)
Division 16660524 · Oct 22, 2019
Continuation 15806883 · Nov 8, 2017
Provisional Application 62419813 · Nov 9, 2016
Related Publication 20220057400A1 · Feb 24, 2022
References Cited (26)
US 10481159B2 · Lee · 2019 [cited by applicant]
US 11187704B2 · Lee · 2021 [cited by applicant]
Chang et al, Neoplasia, 2013, vol. 15, No. 7, pp. 848-862 (Year: 2013). [cited by examiner]
Dethlefsen et al. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat; 2013; vol. 138, pp. 657-664 (Year: 2013). [cited by examiner]
Salgado et al. Circulating interleukin-6 predicts survival in patietns with metastatic breast cancer. International Journal of Cancer, 2003; vol. 103, pp. 642-646 (Year: 2003). [cited by examiner]
Shen et al. The role of ADAM17 in tumorigenesis and progression of breast cancer. Tumor Biology, vol. 37, pp. 15359-15370, published on Sep. 22, 2016 (Year: 2016). [cited by examiner]
Widschwendter. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clinical Cancer Research, 2002, vol. 8, pp. 3065-3074 (Year: 2002). [cited by examiner]
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, 1990, 247:1306-1310 (Year: 1990). [cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L… [cited by examiner]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988). [cited by examiner]
Bork. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Research, 2000; 10:398-400 (Year: 2000). [cited by examiner]
Anderson et al, (Proceedings: AACR 101st Annual Meeting 2010 (Year: 2010). [cited by examiner]
Burke et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene vol. 20, pp. 7925-7934 (2001) (Year: 2001). [cited by examiner]
Cochaud, S., Giustiniani, J., Thomas, C. et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep 3, 3456 (2013) (Year: 2013). [cited by examiner]
Anderson, K.S. et al. (2010). Abstract 1906:IL-6-mediated activation of STAT3 inhibits APC and T cell function in metastatic breast cancer, [cited by applicant]
Bachelot, T. et al. (Jun. 2003). “Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients,” [cited by applicant]
Chang, Q. et al. (Jul. 2013). “The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis,” [cited by applicant]
Dethlefsen, C. et al. (Apr. 2013, e-published Mar. 27, 2013). “The role of intratumoral and systemic IL-6 in breast cancer,” [cited by applicant]
Dienz, O. et al. (Jan. 2009, e-published Oct. 8, 2008). “The effects of IL-6 on CD4 T cell responses,” [cited by applicant]
Heo, T.H. et al. (Mar. 29, 2016). “Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer,” [cited by applicant]
Magi, B. et al. (2005). “Immunoblotting Techniques” in [cited by applicant]
Salgado, R. et al. (Feb. 20, 2003). “Circulating interleukin-6 predicts survival in patients with metastatic breast cancer,” [cited by applicant]
Shen, H. et al. (2016). “The role of ADAM17 in tumorigenesis and progression of breast cancer,” [cited by applicant]
Wang, L. et al. (2019). “Connecting blood and intratumoral T [cited by applicant]
Wang, L. et al. (Feb. 2020, e-published Jan. 22, 2020). Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes, [cited by applicant]
Widschwendter, A. et al. (Oct. 2002). “Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer,” [cited by applicant]